Survodutide is a dual-target agonist of the glucagon receptor (GCGR) and the GLP-1 receptor (GLP-1R), mainly used to treat obesity and related metabolic diseases. It is jointly developed by Boehringer Ingelheim and Zealand Pharma and is currently in Phase III clinical trials.
Survodutide Mechanism of action and advantages
Dual receptor activation mechanism: By activating GCGR and GLP-1R at the same time, it can not only reduce appetite but also increase energy consumption, and has a stronger weight loss effect than single-target agonists.
Liver targeting: Directly acts on the liver to improve fat metabolism, inflammation and fibrosis, especially in the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Clinical trial data
Weight loss effect: Phase II trials showed that after 46 weeks of treatment, the average weight loss of patients was 18.7% (about 19.5 kg), and 98% of the subjects lost more than 5%^5.
MASH treatment breakthrough: In the 48-week trial, 62% of patients treated with a 4.8 mg dose achieved MASH improvement without worsening fibrosis, significantly better than the placebo group (14%).
